Sinovac Biotech annual return on equity
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Sinovac Biotech Return on Equity (ROE) Growth & History (SVA)
Sinovac Biotech's return on equity was −3.13% for fiscal 2025.
View full Sinovac Biotech company overviewSinovac Biotech annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −3.13% | −3.62 pp |
| 2024 | 2024-12-31 | 0.49% | +0.65 pp |
| 2023 | 2023-12-31 | −0.16% | −0.33 pp |
| 2022 | 2022-12-31 | 0.17% | −166.59 pp |
| 2021 | 2021-12-31 | 166.75% | +145.54 pp |
| 2020 | 2020-12-31 | 21.21% | +4.80 pp |
| 2019 | 2019-12-31 | 16.41% | +5.65 pp |
| 2018 | 2018-12-31 | 10.77% | −8.57 pp |
| 2017 | 2017-12-31 | 19.34% | +19.84 pp |
| 2016 | 2016-12-31 | −0.50% | +0.64 pp |
| 2015 | 2015-12-31 | −1.14% | +0.05 pp |
| 2014 | 2014-12-31 | −1.19% | −7.23 pp |
| 2013 | 2013-12-31 | 6.04% | +21.18 pp |
| 2012 | 2012-12-31 | −15.14% | −14.48 pp |
| 2011 | 2011-12-31 | −0.66% | +7.41 pp |
| 2010 | 2010-12-31 | −8.07% | — |
Sinovac Biotech return on equity trends
Over the last five fiscal years, Sinovac Biotech's return on equity decreased from 21.21% to −3.13%, a change of −24.35 percentage points.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Sinovac Biotech source filings ↗